Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines

Kazuaki Machioka; Kouji Izumi; Yoshifumi Kadono; Hiroaki Iwamoto; Renato Naito; Tomoyuki Makino; Suguru Kadomoto; Ariunbold Natsagdorj; Evan T. Keller; Jian Zhang; Atsushi Mizokami

doi:10.18632/oncotarget.24609

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines

Kazuaki Machioka, Kouji Izumi, Yoshifumi Kadono, Hiroaki Iwamoto, Renato Naito, Tomoyuki Makino, Suguru Kadomoto, Ariunbold Natsagdorj, Evan T. Keller, Jian Zhang and Atsushi Mizokami _

PDF | HTML | How to cite

Oncotarget. 2018; 9:16185-16196. https://doi.org/10.18632/oncotarget.24609

Metrics: PDF 1736 views | HTML 3309 views | ?

Abstract

Kazuaki Machioka1, Kouji Izumi1, Yoshifumi Kadono1, Hiroaki Iwamoto1, Renato Naito1, Tomoyuki Makino1, Suguru Kadomoto1, Ariunbold Natsagdorj1, Evan T. Keller2, Jian Zhang3 and Atsushi Mizokami1

1Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, 920-8640, Japan

2Department of Urology, School of Medicine and Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA

3Center for Translational Medicine, Guangxi Medical University, Medical Science Research Building, Nanning, Guangxi, 530021, P. R. China

Correspondence to:

Atsushi Mizokami, email: [email protected]

Keywords: prostate cancer; CRPC; cabazitaxel-resistant; MDR1

Received: January 11, 2018 Accepted: February 26, 2018 Epub: March 05, 2018 Published: March 23, 2018

ABSTRACT

Once castration-resistant prostate cancer (CRPC) become resistant for cabazitaxel treatment, the patients are obliged to best supportive care. Therefore, the elucidation of the mechanism of the cabazitaxel-resistance and the conquest are important themes to improve the prognosis of the patients. Then we tried to establish cabazitaxel-resistant CRPC cell lines and characterized them. We established two cabazitaxel-resistant cell lines, PC-3-TxR/CxR and DU145-TxR/CxR from PC-3-TxR and DU145-TxR cell lines previously we established. PC-3-TxR/CxR and DU145-TxR/CxR cells became resistant for cabazitaxel by 11.8-fold and 4.4-fold, respectively. The TxR/CxR cells showed cabazitaxel-resistant using SCID mice in vivo. Although expression of multi-drug resistance gene 1 (MDR1) was up-regulated in DU145-TxR compared with DU145 cells, it was not up-regulated in DU145-TxR/CxR cells any more. In contrast, expression of MDR1 gene was up-regulated in PC-3-TxR compared with PC-3 cells and it was further up-regulated in PC-3-TxR/CxR compared with PC-3-TxR cells. Comparison of cDNA microarray between PC-3-TxR and PC-3-TxR/CxR cells or between DU145-TxR and DU145-TxR/CxR cells revealed that many genes were up-regulated or down-regulated. Finally, knockdown of MDR1 recovered the sensitivity to cabazitaxel not only in PC-3-TxR/CxR cells but also DU145-TxR/CxR cells. Together, regulation of MDR1 gene is important for conquest of the cabazitaxel-resistance.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24609

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines

Abstract